DNA RNA and Cells
4 January 2024
AskBio Phase Ib trial of AB-1005 gene therapy in patients with Parkinson’s disease meets primary endpoint3 January 2024
Genascence Announces Initiation of Phase 1b Clinical Trial of GNSC-001 Gene Therapy for Knee Osteoarthritis (OA)3 January 2024
Belief BioMed Successfully Completed Dosing of First Subject in the Registrational Clinical Trial for Hemophilia A2 January 2024
Voyager Therapeutics Enters Capsid License Agreement and Strategic Collaboration with Novartis to Advance Novel Gene Therapies27 December 2023
Innovent and SanegeneBio Enter Strategic Collaboration to Develop siRNA Drug for the Treatment of Hypertension26 December 2023
AstraZeneca to acquire Gracell, furthering cell therapy ambition across oncology and autoimmune diseases22 December 2023
AlloVir Provides Updates on Phase 3 Clinical Development Program for Posoleucel, an Allogeneic Virus-Specific T Cell Therapy22 December 2023
MeiraGTx Announces Asset Purchase Agreement Involving its AAV-RPGR Collaboration for up to $415 million22 December 2023
U.S. FDA Approves Label Update for Kite’s Yescarta® CAR T-Cell Therapy to Include Overall Survival Data21 December 2023
CellVax Submits IND Application for Individualized Cell-based Immunotherapy FK-PC101 with Support of Theragent21 December 2023
Arrowhead Pharmaceuticals Files for Regulatory Clearance to Initiate Phase 1/2a Study of ARO-CFB for Complement Mediated Kidney Disease21 December 2023
JCR Pharmaceuticals and Takeda Pharmaceuticals Announce Discontinuation of Gene Therapy Collaboration20 December 2023
uniQure Announces Update on Phase I/II Clinical Trials of AMT-130 Gene Therapy for the Treatment of Huntington’s Disease20 December 2023
Galapagos announces start of PAPILIO-1 Phase 1/2 multiple myeloma study of point-of-care manufactured BCMA CAR-T candidate, GLPG530119 December 2023
Ethris Initiates First-in-Human Dosing in Phase 1 Study of ETH47 for the Treatment of Virus-Induced Asthma19 December 2023
PepGen Announces First Patient Dosed in Phase 1 FREEDOM-DM1 Clinical Trial of PGN-EDODM1 for Myotonic Dystrophy Type 1 (DM1)19 December 2023
Carina Biotech Doses First Patient in Phase 1/2a Clinical Trial of LGR5-Targeted CAR-T Cell TherapyNews Channels
Newsletter
La Merie Biologics
La Merie Publishing releases a weekly newsletter with a focus on biopharmaceutical research and development.
SubscribeNewsletter
New Product Alert
La Merie Publishing offers an e-mail notification service about the release of new products of La Merie Publishing. This New Product Release Alert also informs about the release of FREE reports produced by La Merie Publishing.
SubscribeFeatured reports